gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin protect ip aggress
highlight week june june voyag neutral announc restructur
collabor sanofi genzym unrat wherebi sanofi genzym return right voyag aav-
base gene therapi gt program huntington diseas hd friedreich ataxia fa given re-alloc
resourc wholly-own hd program voyag seek partner amyotroph later
sclerosi al gt program longer plan file ind indic toolgen buy announc
plan transact wherebi genexin unrat acquir share toolgen establish merg
entiti toolgenexin combin entiti merg toolgen gene edit capabl genexin expertis
immunotherapi develop cell gene-bas therapi arcturu therapeut buy announc expans
exist research collabor unrat first establish includ new
rare diseas target arcturu receiv mm up-front ultragenyx compris mm cash payment
mm sale mm share ultragenyx price per share chardan host leadership
call buy chardan top pick manag june key take-away us see
may underappreci market compani begin protect ip aggress
note unrat may relev theme replay call avail
look forward june june june peripher nerv societi pn host annual
meet genoa program includ repres unrat
buy unrat june parent project muscular dystrophi annual
confer take place orlando program featur repres ns pharma privat unrat
sarepta unrat solid bioscienc neutral wave life scienc unrat june
annual huntington diseas societi america hdsa convent take place boston agenda
includ repres unrat uniqur buy neutral wave
life scienc unrat june juli european academi neurolog ean host annual congress
oslo program featur repres unrat buy atara
unrat avexi novarti unrat compani unrat
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
gene express may special resist neutral
articl publish june scienc translat medicin offer perspect genethon privat
scientist regard studi uniqur buy chardan top pick publish may molecular therapi
method clinic develop recal part thesi uniqur relat properti make
vector less suscept neutral antibodi immunogen issu uniqur studi conduct
majowicz et al use luciferase-bas assay demonstr patient treat clinic trial
uniqur gt hemophilia test neg pre-exist neutral
antibodi nab base gfp-base assay use trial actual posit nab
luciferase-bas assay far sensit gfp-base assay explain patient previous
test neg nab howev correl seen presenc nab efficaci
furthermor team perform studi non-human primat nhp posit nab
correl seen titer nab therapeut efficaci subsequ studi
patient exclud phase iib clinic trial patient trial pre-
exist nab achiev therapeut activ post-treat see may research
pleas refer import disclosur inform regul analyst certif found page report
work signific result challeng long-held belief presenc nab prevent liver
transduct nab often-discuss hurdl system administr aav-bas seroposit
usual exclus criterion clinic trial perspect articl highlight data suggest potenti
resist neutral referenc also trial initi unrat
patient pre-exist nab enrol receiv gt hemophilia author note
potenti resist principl may allow inclus seroposit individu thu expand
number patient treatabl aav gene therapi
neutral pt updat derisk collabor june amusa
increas price target reflect econom collabor
bigger-cap partner unrat neurocrin maintain neutral rate due view voyag
rel import catalyst certain key valuat inflect point year away
compani also announc restructur gt relationship unrat sanofi genzym sanofi
genzym give right voyag aav-bas gt program hd fa exchang mm
payment plu low-single-digit royalti hd restructur us net neg particularli signal
insid decid opt program us littl given return
buy mm royalti say ip june amusa
updat model account royalti gt ind
activ phase i/ii trial parkinson diseas patient mutat addit potenti royalti
own mm share prevail unrat could valu mm
base propos maximum offer price per share june file
continu find unusu bear model worst case ip exampl oft-
echo bear view relat durat may collect royalti
extern license program bear critic durat econom product
consensu model clearli mm estim extrem upwardli skew risk-reward dynam
toolgen buy pt krw ge continu genexine/toolgen deal june livshit
toolgen announc plan transact understand genexin unrat acquir share
toolgen establish merg entiti toolgenexin integr compani leverag toolgen gene edit
capabl togeth genexin expertis immunotherapi develop cell gene-bas therapeut
move could equip toolgen exin expertis new therapeut vertic along broader exposur
list kosdaq
detail transact english languag sourc limit understand deal anticip close
august list kosdaq effect septemb per factset term deal
genexin issu share everi share toolgen agre acquir toolgen inc
billion million stock
arcturu announc expans exist research collabor unrat
two compani first enter collabor agreement discov develop mrna dna sirna
therapeut new expand agreement ultragenyx access rare diseas target
connect amend agreement arcturu receiv mm up-front ultragenyx mm cash
payment mm sale mm share ultragenyx price per share
believ expand collabor agreement ultragenyx provid addit extern valid
arcturu enabl technolog believ notabl term agreement ultragenyx
renegoti posit progress achiev initi collabor project
buy leadership calldefend ip increas prioriti june amusa
particip chardan leadership call june replay call avail overal
believ leadership call support high convict feel comment
intellectu properti particular under-appreci market note follow key takeaway
 upbeat compani progress past year compani focu
intern pipelin activ clinical-stag program start program
report data end point expect program clinic
page
 plan begin protect intellectu properti aggress
comment probabl potenti program exist may use unlicens
technolog point histori note unrat construct may
relev theme importantli rule partnership sarepta
 shown proof concept wet age-rel macular degener target larg
unmet medic need market treatment burden aim increment reduc inject
frequenc eylea compar lucenti elimin need continu repeat dose altogeth
genet medicin news june june
cyad unrat present data eha car-t tx r/r aml md june
celyad announc present congress european hematolog associ eha data
think phase trial deplethink phase trial autolog
cell therapi express receptor relapsed/refractori r/r acut myeloid leukemia aml
myelodysplast syndrom md think trial use regimen without precondit chemotherapi
wherea deplethink trial use regimen precondit
think trial may preliminari anti-leukem activ observ evalu patient
exhibit object respons includ patient durat respons day patient
cohort receiv denser schedul infus without precondit dose cell
evalu patient experienc diseas stabil experienc diseas progress patient
evalu safeti cohort experienc grade cytokin releas syndrom rapid resolut
treatment patient experienc grade infus reaction result cohort patient
treat dose cell without precondit expect
deplethink trial initi cohort enrol patient receiv singl infus cell
precondit chemotherapi time interv day precondit dose
may evalu patient experienc diseas stabil patient experienc grade patient
experienc grade infus reaction result higher dose cohort singl infus cell
precondit expect
unrat announc patient dose pi trial car-t tx lymphoma june
buy complet enrol illuminate-a piii trial rnai tx lumasiran june
unrat present preclin data eshg aavhsc-bas gt pku june
abu buy announc appoint william collier replac current presid ceo june
onc unrat announc collabor roswel park ivm tavo-plu apollo june
unrat announc expans leadership team promot erik harri june
unrat announc appoint heidi hagen board director june
ise neutral announc manufactur agreement unrat gmp aav vector june
unrat initi dose pi trial gt danon diseas june
buy announc approv japan rnai tx onpattro hattr polyneuropathi june
unrat receiv fda track design gt diseas june
trakcel privat announc partnership match biotherapi privat gt suppli chain june
unrat announc price mm initi public offer june
sight fp neutral appoint dr maritza mcintyr sofinnova partner board director june
unrat announc price mm initi public offer june
buy announc gt develop manufactur partnership yposkesi privat june
buy announc appoint dr bernd hopp vice-president global medic affair june
uchicago publish human protein-bas crispr-cas-inspir rna target system cirt june
abu buy announc regulatori clearanc initi pia/ib clinic trial rnai tx hbv june
selb unrat appoint scott myer board director june
page
buy report updat rnai therapeut platform includ oral administr june
buy present data updat phase studi rnai tx dcr-phxc june
dicerna present oxalosi hyperoxaluria foundat ohf intern hyperoxaluria workshop updat
result phase trial rnai therapeut dcr-phxc primari hyperoxaluria type
type
data consist previou result patient receiv singl dose mg/kg dcr-phxc
administ subcutan may mean maxim reduct urinari oxal
rang patient patient normal excret mmol achiev
post-dos time point patient near-norm mmol achiev
patient treat dcr-phxc dose mg/kg dose mg/kg
mean maxim reduct urinari oxal rang patient achiev
seriou advers event sae report patient patient treat patient experienc mild
moder inject site reaction overal dcr-phxc well toler investig expect multi-
dose regimen dcr-phxc may offer potenti pronounc sustain reduct urinari oxal
buy receiv orphan drug design rnai tx treatment fc june
compani mention report
page
select catalyst genet medicin coverag
figur alnylam arrowhead dicerna meira gtx expect initi trial
provid program updat phase i/ii valen trial crigler-najjar syndrom
select optim dose xlmtm
dcr-phxc initi long-term registr roll-ov studi ph
file ind cta pomp diseas
aro-aat initi phase ii/iii studi liver diseas
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
initi trial malign
complet phase i/ii studi dystroph epidermolysi bullosa deb
top-lin phase ii data treat deb patient
complet ind-en studi diseas
dose patient phase studi mp
lumasiran initi illuminate-b -c phase trial
givosiran file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
page
select catalyst genet medicin coverag
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
report dose escal data pi/ii trial achm/xlrp
report preliminari data phase i/ii studi batten diseas
initi phase i/ii trial dmd
submit ema lhon
report interim efficaci readout phase oval trial ovarian cancer
xlrp report interim data expans arm phase i/ii trial xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
initi phase i/ii trial autosom recess congenit ichthyosi
file ind ornithin transcarbamylas over-the-counter defici
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
initi phase i/ii trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
file ind huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
file ind rett syndrom
initi phase i/ii trial leukocyt adhes deficiency-i
initi phase trial recess dystroph epidermolysi bullosa
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
begin patient dose phase trial
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valrox present full piii top-line data hem
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end june vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm voyag genet therapytickerratingccm ptupsideclosechang changemc mm arcturu gene editingtickerratingccm ptupsideclosechang changemc mm precis pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
